In an effort to demonstrate the clinical relevance of these data, Huang et al. tested the effect of a single dose of a neoadjuvant PD-1 blockade in patients diagnosed with stage III/IV resectable melanoma, with 8 out of 27 patients achieving a complete or major pathological response. This evidence concerns the gene RPL17 and melanoma.